Press Releases
-
09/28/13Jennerex Announces Expansion of Intellectual Property Portfolio
-
09/03/13Jennerex announces preliminary results from TRAVERSE, a Phase 2 study in second-line advanced liver cancer
-
05/23/13Jennerex Completes $21.6 Million Private Placement
-
05/21/13Jennerex Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
-
05/15/13Jennerex Presents Pexa-Vec Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting
-
05/15/13Jennerex Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to Induce Functional Anti-cancer Immunity in Patients with Diverse Tumor Types
-
05/08/13Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
-
04/09/13Jennerex Announces Presentation of Data Demonstrating Pexa-Vec's Vascular Targeting Mechanism
-
02/25/13Jennerex and Lee's Pharmaceutical Announce Expansion of Partnership for Additional Pexa-Vec Indications in China
-
02/11/13Jennerex Announces Cancer Research Publication Demonstrating Vascular Targeting Mechanism of Action of Lead Product Candidate, Pexa-Vec (JX-594)
-
02/10/13Jennerex Announces Nature Medicine Publication Highlighting Randomized Overall Survival Benefit of Lead Product Candidate, Pexa-Vec (JX-594) in Patients with Advanced Hepatocellular Carcinoma (HCC)
-
11/27/12Jennerex’s Drug Candidate, JX-929, Named as One of the Top 10 Oncology Projects to Watch
-
11/08/12Jennerex to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
- 09/17/12Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX594 in Sorafenib-Refractory Liver Cancer Patients
- 07/25/12Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
- 06/28/12Jennerex Appoints Dr. Laurent Fischer as President and
Chief Executive Officer - 06/04/12Jennerex Presents JX-594 Clinical Data at 2012 American Society of Clinical Oncology Annual Meeting
- 05/16/12Jennerex Announces Data Presentations Relating to Oncolytic Virus JX-594 at American Society of Clinical Oncology Annual Meeting
- 04/17/12Jennerex Elects Dr. Mitchell H. Gold to Board of Directors
- 03/20/12Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
- 02/08/12Jennerex, Inc. to Present at the 14th Annual BIO CEO & Investor Conference
- 02/07/12Jennerex Publishes Data on JX-594 Cancer Targeting Mechanisms
- 12/21/11Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
- 11/05/11Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer
- 11/04/11Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
- 11/02/11Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
- 09/06/11Jennerex Presents Interim Clinical Data of JX-594 Followed by Sorafenib Demonstrating Tumor Responses in Liver Cancer
- 08/31/11Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX 594 to Tumors
- 08/11/11Jennerex Completes Successful Private Placement for Gross Proceeds of $8.6 Million
- 08/01/11Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
- 05/19/11Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
- 05/12/11Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
- 04/20/11Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination with Sorafenib in Advanced Liver Cancer
- 04/05/11Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
- 04/04/11Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients with Liver Tumors
- 02/22/11Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
- 01/19/11Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
